Having trouble accessing articles? Reset your cache.

Patient deaths reported in Tecentriq, Cotellic combo arm of mCRC trial

Roche (SIX:ROG; OTCQX:RHHBY) said it temporarily halted recruitment in the Phase II MODUL trial to treat metastatic colorectal cancer following four deaths, including a case of treatment-related cardiogenic

Read the full 281 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE